ATE501278T1 - METHOD OF USING IL-21 - Google Patents

METHOD OF USING IL-21

Info

Publication number
ATE501278T1
ATE501278T1 AT06792239T AT06792239T ATE501278T1 AT E501278 T1 ATE501278 T1 AT E501278T1 AT 06792239 T AT06792239 T AT 06792239T AT 06792239 T AT06792239 T AT 06792239T AT E501278 T1 ATE501278 T1 AT E501278T1
Authority
AT
Austria
Prior art keywords
individual
predicting
therapy
patient
detecting
Prior art date
Application number
AT06792239T
Other languages
German (de)
Inventor
Hans Yssel
Laurence Gugliemi
Jerome Pene
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE501278T1 publication Critical patent/ATE501278T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

There is provided an in vitro method of predicting a differential therapeutic response to IL-21 in an individual in need of IL-21 therapy, comprising detecting, in a biological sample from the patient, an allelic variant of the individual's IL-21 receptor gene.
AT06792239T 2005-09-22 2006-09-22 METHOD OF USING IL-21 ATE501278T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71938805P 2005-09-22 2005-09-22
PCT/EP2006/009239 WO2007039147A1 (en) 2005-09-22 2006-09-22 Methods of using il-21

Publications (1)

Publication Number Publication Date
ATE501278T1 true ATE501278T1 (en) 2011-03-15

Family

ID=37649383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06792239T ATE501278T1 (en) 2005-09-22 2006-09-22 METHOD OF USING IL-21

Country Status (10)

Country Link
US (2) US20070111239A1 (en)
EP (2) EP1937838B1 (en)
JP (1) JP5208746B2 (en)
AT (1) ATE501278T1 (en)
AU (1) AU2006299141B2 (en)
CA (1) CA2620338A1 (en)
DE (1) DE602006020601D1 (en)
ES (1) ES2360728T3 (en)
IL (1) IL189597A (en)
WO (1) WO2007039147A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848819A4 (en) * 2005-02-16 2010-01-06 Genetic Technologies Ltd Methods of genetic analysis involving the amplification of complementary duplicons
ES2360728T3 (en) * 2005-09-22 2011-06-08 Inserm (Institut National De La Santé Et De La Recherche Medicale) METHODS OF USE OF IL-21.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322266T2 (en) 1992-04-03 1999-06-02 Perkin Elmer Corp SAMPLES COMPOSITION AND METHOD
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5571676A (en) 1995-06-07 1996-11-05 Ig Laboratories, Inc. Method for mismatch-directed in vitro DNA sequencing
US5773346A (en) 1995-12-06 1998-06-30 Micron Technology, Inc. Semiconductor processing method of forming a buried contact
US6803451B2 (en) 1998-09-23 2004-10-12 Zymogenetics, Inc. Cytokine receptor zalpha11 polypeptides
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2003251633A1 (en) * 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
EP1782823A3 (en) * 2002-10-11 2007-05-16 Novo Nordisk A/S IL-21 peptides and nucleic acids
BR0315134A (en) * 2002-10-11 2005-08-16 Novo Nordisk As Uses of il-21 and an il-21 Polypeptide
JP4664684B2 (en) 2002-12-13 2011-04-06 ザイモジェネティクス, インコーポレイテッド Production of IL-21 in prokaryotic hosts
ES2360728T3 (en) * 2005-09-22 2011-06-08 Inserm (Institut National De La Santé Et De La Recherche Medicale) METHODS OF USE OF IL-21.

Also Published As

Publication number Publication date
AU2006299141B2 (en) 2011-11-24
AU2006299141A1 (en) 2007-04-12
US20100291029A1 (en) 2010-11-18
US20070111239A1 (en) 2007-05-17
JP5208746B2 (en) 2013-06-12
IL189597A0 (en) 2008-08-07
ES2360728T3 (en) 2011-06-08
WO2007039147A1 (en) 2007-04-12
JP2009508506A (en) 2009-03-05
EP1937838B1 (en) 2011-03-09
CA2620338A1 (en) 2007-04-12
IL189597A (en) 2012-06-28
EP2311995A1 (en) 2011-04-20
EP1937838A1 (en) 2008-07-02
DE602006020601D1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
RS51859B (en) Method for predicting the response to a treatment with a her dimerization inhibitor
ATE390925T1 (en) USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT MYCOBACTERIAL DISEASES
EP2239262A3 (en) Fused ring heterocycle kinase modulators
ATE406575T1 (en) METHOD FOR DETECTING DRUG SENSITIVITY IN PATIENTS WITH INFLAMMATORY DISEASES
ATE406351T1 (en) CONDENSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS
NO20052955L (en) Treatment of Huntington's disease with EPA
CY2015025I1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
BR0111125A (en) Nrg-2 Nucleic Acid Molecules, Polypeptides, and Diagnostic and Therapeutic Methods
DE60323300D1 (en) Apparatus for the early detection of ischemic heart disease
MX2007006529A (en) Selecting patients for therapy with a her inhibitor.
MX2009003562A (en) Elisa for vegf.
ATE329610T1 (en) ANTI-APRIL ANTIBODIES AND HYBRIDOMA CELLS
ATE359508T1 (en) SCREENING METHODS USING ZEBRAFISH AND THE BLOOD-BRAIN BARRIER
DE602005008325D1 (en) Quantification of enzyme activity by means of planar waveguides
DE602006012995D1 (en) BREAST CANCER DIAGNOSTIC PROCEDURE
DK2005162T3 (en) screening Method
Ardakani et al. Quantifying the correlation between spatially defined oxygen gradients and cell fate in an engineered three-dimensional culture model
ATE527378T1 (en) ANTISENSE MODULATION OF P38 MITOGEN-ACTIVATED PROTEIN KINASE EXPRESSION
DK1526840T3 (en) Nanoparticles for DNA administration to a target organ
DE602005002673D1 (en) Nucleotide sequence variation in the NS5A gene as a marker
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases
ATE501278T1 (en) METHOD OF USING IL-21
ATE508201T1 (en) METHOD FOR GENERATING A GENETICALLY MODIFIED ORGANISM FOR ACTIVE SUBSTANCE SCREENING
EP2508886A3 (en) Means and methods for classifying samples of multiple sclerosis patients
DK1991696T3 (en) Method for Diagnosing a Plant in Patients with Disseminated Sclerosis for Interferon Therapy Susceptibility and for Diagnosing Disseminated Sclerosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1937838

Country of ref document: EP